Close Menu

This article has been updated to note that the median progression-free survival was more than double in the Keytruda arm in Keynote-177 compared to the comparator arm, not nearly double.

NEW YORK – Merck on Tuesday said the European Commission has approved pembrolizumab (Keytruda) as a first-line therapy for metastatic colorectal cancer patients in the European Union whose tumors are microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.